Bharat Biotech Seeks DCGI Nod for Covaxin Booster Trial Among Children Aged 2 to 18
- Bharat Biotech seeks trial for precautionary dose in children between 2 to 18 years.
- Submitted an application on April 29th to DCGI.
- 2,19,348 individuals above 18 years have been administered the precautionary dose.
New Delhi: Bharat Biotech has approached the DCGI seeking permission to conduct a booster trial of its COVID-19 vaccine, COVAXIN for kids between 2 to 18 years. The precaution dose of Covaxin and Covishield is being administered to all those above 18 years old and have completed nine months after the second dose.
“The Hyderabad-based firm had on April 29 submitted an application to DCGI seeking permission to conduct phase 2/3 trial to evaluate the safety, reactogenicity and immunogenicity of Covaxin as a booster dose in healthy volunteers aged 2 to 18 years,” a source in the know said. The study is likely to be conducted at six sites, including AIIMS Delhi and Patna.
India so far, has immunized 189.60 Crore (1,89,60,56,429) beneficiaries under its nationwide vaccination program. On April 10, India began administering the precaution jabs to all aged above 18 at private vaccination centres. So far, 2,19,348 have been jabbed with the preacutionary dose.